Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLK286 + Carboplatin in Recurrent Ovarian Cancer
NCT00051948Phase 2Completed
- Sponsor
- Telik, Inc.
- Start
- Jan 2003
- Primary completion
- Jan 2005
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canfosfamide in ovarian cancer, sponsored by Telik, Inc. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate. Started Jan 2003; status: completed.
02
Drugs
canfosfamide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00051948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051948.